Clinical trial · Interventional
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
NCT02490748CI-TRIAL-00021067active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytokine-induced killer cells | Biological | — | UNRESOLVED |
| Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- RFA alone
- description
- Patients undergo radiofrequency ablation alone.
- type
- EXPERIMENTAL
- label
- RFA+CIK
- description
- Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
- interventionNames
- Procedure: Radiofrequency ablation
- Biological: Cytokine-induced killer cells
Primary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- 1 year
- description
- Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer. they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer). Exclusion Criteria: * studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.
References
Publications (0)
Data not yet available
No reference posted for this study.